Barinthus Biotherapeutics
BRNS
15 hedge funds and large institutions have $60.2M invested in Barinthus Biotherapeutics in 2021 Q3 according to their latest regulatory filings, with 1 funds opening new positions, 4 increasing their positions, 4 reducing their positions, and 5 closing their positions.
3% more capital invested
Capital invested by funds: $58.3M → $60.2M (+$1.89M)
0.87% more ownership
Funds ownership: 13.49% → 14.35% (+0.87%)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
0% more repeat investments, than reductions
Existing positions increased: 4 | Existing positions reduced: 4
21% less funds holding
Funds holding: 19 → 15 (-4)
80% less first-time investments, than exits
New positions opened: 1 | Existing positions closed: 5
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
GCM
Ghisallo Capital Management
Boston,
Massachusetts
|
+$161K |
| 2 |
IIM
Ipswich Investment Management
Beverly,
Massachusetts
|
+$125K |
| 3 |
Morgan Stanley
New York
|
+$109K |
| 4 |
EMG
ETF Managers Group
Summit,
New Jersey
|
+$42.7K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
MIM
Monashee Investment Management
Boston,
Massachusetts
|
-$2.22M |
| 2 |
BlackRock
New York
|
-$839K |
| 3 |
Tudor Investment Corp
Stamford,
Connecticut
|
-$639K |
| 4 |
CCM
CAAS Capital Management
New York
|
-$604K |
| 5 |
Squarepoint
New York
|
-$420K |
BRNS Hedge Fund Activity: Q3 2021 in Review
15 of the 5,713 institutional investors tracked by Wall St. Rank reported a position in Barinthus Biotherapeutics (BRNS) for Q3 2021, worth a combined $60.2M — up 3.2% from $58.3M a quarter earlier.
Sellers outnumbered buyers: 5 funds closed out of BRNS and 1 opened new positions — a net loss of 4 holders — while 4 trimmed existing stakes and 4 added.
The largest buyer was Ghisallo Capital Management, adding an estimated $161K. The largest seller was Monashee Investment Management, exiting entirely with an estimated $2.22M sold.
- 15 institutional investors held Barinthus Biotherapeutics (BRNS) as of Q3 2021, down from 19 in Q2 2021.
- Funds reported $60.2M of Barinthus Biotherapeutics stock for Q3 2021, up 3.2% quarter-over-quarter.
- 1 fund opened new Barinthus Biotherapeutics positions in Q3 2021 and 5 closed out, a net change of -4 holders.
- The largest Barinthus Biotherapeutics buyer in Q3 2021 was Ghisallo Capital Management, an estimated $161K added.
- The largest Barinthus Biotherapeutics seller in Q3 2021 was Monashee Investment Management, an estimated $2.22M sold.
Based on aggregated 13F filings for Q3 2021.